Dental products company Envista Holdings (NYSE: NVST) announced better-than-expected revenue in Q1 CY2026, with sales up 14.4% year on year to $705.5 million. Its non-GAAP profit of $0.36 per share was 14.9% above analysts’ consensus estimates.

Is now the time to buy NVST? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Envista’s first quarter results saw sales increase driven by strong growth across orthodontics, diagnostics, and consumables, supported by new product launches and operational improvements. However, the negative market reaction reflected investor caution, as management pointed to macroeconomic uncertainty and the impact of tariffs as ongoing challenges. CEO Paul Keel noted the company’s gains “were partly due to improved execution in growth, operations, and people,” while also acknowledging the benefits from additional billing days and focused cost controls.

Looking forward, Envista’s guidance is shaped by cautious optimism amid persistent external risks. Management reiterated plans to invest in R&D and commercialization, aiming to drive new product momentum, particularly in implants and orthodontics. CFO Eric Hammes cautioned that “headwinds from tariffs and potential inflation due to Middle East tensions remain embedded in our outlook,” but the company expects productivity gains and supply chain adaptations to help offset these pressures. Investments in digital diagnostics and international expansion are expected to remain focal points.

Key Insights from Management’s Remarks

Management cited broad-based portfolio growth, new product introductions, and disciplined operational execution as key drivers, while highlighting continued uncertainty from global tariffs and macro volatility.

• Orthodontics and diagnostics growth: Both segments posted double-digit increases, driven by the Spark clear aligner expansion—now launched in Japan—and AI-powered updates to the DEXIS imaging platform, which enhances diagnostic accuracy and workflow efficiency for clinicians.
• Implant business headwinds: The implants division grew mid-single digits outside China, but overall progress was tempered by destocking and pricing pressure in China ahead of government volume-based procurement (VBP) changes. Management expects near-term volatility as VBP implementation approaches, with potential for longer-term market share gains.
• Product innovation pipeline: Recent launches such as the Nobel S Series implant and DTX Studio Clinic with enhanced AI are gaining traction, with management viewing these as central to future growth. The newly acquired Versah osseodensification technology broadens the implant offering and is expected to be accretive to margins and growth.
• Operational productivity: The Envista Business System, a continuous improvement model, contributed to manufacturing gains and a 100 basis point gross margin expansion. G&A cost discipline, including a $35 million reduction last year, provided further leverage for reinvestment.
• Tariff and input cost mitigation: Management described ongoing efforts to offset rising tariff and fuel costs by optimizing supply chains and using pricing actions where necessary. They estimate mid-single-digit million dollar exposure to fuel-related inflation, but believe mitigation plans are sufficient to contain risks within current guidance.

Drivers of Future Performance

Envista’s outlook is shaped by continued investment in product innovation and commercial execution, balanced against external risks from tariffs, VBP in China, and potential inflation.

• Tariffs and macro uncertainty: Management expects tariff-related costs to persist in 2026, with mitigation through supply chain adjustments and pricing. Potential inflation from Middle East tensions is being actively managed, and management remains vigilant about broader macro risks that could impact dental procedure volumes and input costs.
• China VBP process: The timing and impact of China’s volume-based procurement on implants and orthodontics remain uncertain. Management is planning for short-term revenue and margin compression as channel partners reduce inventories, but anticipates volume recovery and market share gains as the process matures.
• Continued investment in growth: Envista plans to sustain high levels of investment in R&D and commercialization, focusing on digital diagnostics, Spark clear aligners, and international expansion. Management believes this approach will support long-term growth and margin expansion, even as comps become more challenging in developed markets.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the pace of adoption and clinical feedback for new Spark clear aligner markets and DEXIS AI-powered diagnostics, (2) the operational impact and revenue cadence from tariffs and China’s VBP rollout, and (3) the ability of Envista’s supply chain initiatives to offset inflation and input cost volatility. Progress on international expansion and new product commercialization will also be key signposts.

Envista currently trades at $24.36, down from $27.07 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.